Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 465 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tumor peptide vaccine Clear all
Completed Phase 1Phase 2 Interventional

Biological Therapy in Treating Patients With Prostate Cancer

NCT00002637
View directory record Official record
Conditions
Prostate Cancer
Interventions
aldesleukin, gene-modified tumor cell vaccine therapy, recombinant interferon gamma
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

HER-2 Protein Vaccine in Treating Women With Breast Cancer

NCT00068614
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2/neu peptide vaccine
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 12, 2026, 12:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

NCT00534209
View directory record Official record
Conditions
Lung Cancer
Interventions
Allogeneic B7.1/HLA-A1, Placebo
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hollywood, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Not applicable Interventional Results available

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

NCT00665002
View directory record Official record
Conditions
Leukemia
Interventions
WT-1, Montanide, Sargramostim (GM-CSF)
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

NCT00054912
View directory record Official record
Conditions
Colonic Neoplasms, Colorectal Neoplasms
Interventions
EP2101
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Results available

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

NCT00836407
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ipilimumab, Pancreatic Cancer Vaccine
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 12, 2026, 12:21 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

NCT02950766
View directory record Official record
Conditions
Kidney Cancer
Interventions
NeoVax, Ipilimumab
Drug
Lead sponsor
Patrick Ott, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer

NCT00005630
View directory record Official record
Conditions
Lung Cancer
Interventions
ras peptide cancer vaccine, sargramostim
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

NCT01355393
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim, rintatolimod
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 12, 2026, 12:21 AM EDT
Withdrawn Phase 1 Interventional

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

NCT01386502
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions
p53: 264-272 peptide, CT-011
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

NCT04040231
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
Interventions
Galinpepimut-S, Nivolumab, Sargramostim
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 12, 2026, 12:21 AM EDT
Suspended Phase 3 Interventional

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831
View directory record Official record
Conditions
Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy
Drug · Procedure
Lead sponsor
Favrille
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Beverly Hills, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 12, 2026, 12:21 AM EDT
Not yet recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

NCT07300475
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC
Drug · Biological · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 12, 2026, 12:21 AM EDT
Not listed Phase 1 Interventional

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

NCT00037037
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine, sargramostim, tyrosinase peptide
Biological
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02111941
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 12, 2026, 12:21 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02117024
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Rogers, Arkansas • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 2 Interventional

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

NCT00001685
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
Interventions
GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

NCT00398138
View directory record Official record
Conditions
Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
Interventions
WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
Biological · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019214
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1 Interventional

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

NCT01095848
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Biological
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 12, 2026, 12:21 AM EDT
Recruiting Phase 1 Interventional

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 12, 2026, 12:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT04287868
View directory record Official record
Conditions
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
Interventions
PDS0101, M7824, NHS-IL12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 12, 2026, 12:21 AM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005841
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 12, 2026, 12:21 AM EDT